[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Developmental Disabilities & Disorders |
Developmental Disabilities |
Clinical Trial: Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
This study is no longer recruiting patients.
Purpose
The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Opioid-Related Disorders Substance-Related Disorders | Drug: Buprenorphine | Phase II |
MedlinePlus related topics: Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Uncontrolled
Official Title: Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot
Expected Total Enrollment: 21
Study start: December 1995
Eligibility
Ages Eligible for Study: 21 Years - 55 Years, Genders Eligible for Study: Both
Criteria
Location Information
Connecticut
APT Residential Services Division, New Haven, Connecticut, 06519, United States
Richard Schottenfeld, M.D., Principal Investigator, Yale University
More Information
Record last reviewed: December 1995
Last Updated: March 17, 2005
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000318
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- Accommodations for People with Mental Retardation (Job Accommodation Network)
- Adopting Children with Developmental Disabilities (National Adoption Information Clearinghouse, ACYF, ACF, HHS)

Not Signed In -


